source: Foundation for Women & Girls with Blood Disorders

year: 2024

As we closed 2023, the Food and Drug Administration (FDA) approved two gene therapies to treat sickle cell disease (SCD). These potential curative therapies include CASGEVY™ (exagamglogene autotemcel [exa-cel]) from Vertex Pharmaceuticals Incorporated and CRISPER Therapeutics, and LYFGENIA^TM from bluebirdbio. While there is a lot of excitement for these advances, the impacts of these therapies are not currently known. Like with many therapies, the impact on women and their future fertility are among the unknowns and are areas of concern for individuals living with sickle cell disease and their healthcare providers.

Please join 7-2-1 for this special edition episode, How New Gene Therapies for SCD May Impact Women’s Fertility, with WGSCD LAN Chair, Dr. Alecia Nero and special guest, Dr. Kelly Acharya, a Reproductive Endocrinologist, and Infertility Specialist with Duke Health. Together, they discuss the areas of concern for women and girls living with SCD and consider what the future may hold for those who are able to receive these life-changing treatments so that they may stay informed in the decision-making process.

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder